drugset
drugset / Trial / NCT03779438

17-Alpha-Hydroxyprogesterone Caproate in Pregnant Women With Placenta Previa

NCT03779438 ↗

Unknown 300 enrolled Aswan University Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Purpose to evaluate the effects of intramuscular 17-Alpha-Hydroxyprogesterone Caproate (17-OHPC) for prevention of Emergent Cesarean Delivery in symptomatic Pregnant Women with Placenta Previa

Timeline

Start
2019-01-01
Primary completion
2021-12-31
Completion
2022-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator 17-alpha-hydroxyprogesterone caproate Unknown 250 mg Intramuscular

Indications

placenta praevia